|
| 1 | 1.01 to 1.02- 5-FLUOROURACILE - (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 2 | 5-FLUOROURACIL |
| 3 | 5-FLUOROURACIL |
| 4 | 2.01 to 2.02- 5-FLUOROURACIL (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 5 | 5-FLUOROURACIL |
| 6 | 5-FLUOROURACIL |
| 7 | 3.01 to 3.02- ABEMACICLIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 8 | ABEMACICLIB |
| 9 | ABEMACICLIB |
| 10 | 4.01 to 4.02- BOSUTINIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 11 | BOSUTINIB |
| 12 | BOSUTINIB |
| 13 | 5.01 to 5.03- CABOZANTINIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 14 | CABOZANTINIB |
| 15 | CABOZANTINIB |
| 16 | CABOZANTINIB |
| 17 | 6.01 to 6.03- CARFILZOMIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 18 | CARFILZOMIB |
| 19 | CARFILZOMIB |
| 20 | CARFILZOMIB |
| 21 | 7.01 to 7.02- CHLORAMBUCIL (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 22 | CHLORAMBUCIL |
| 23 | CHLORAMBUCIL |
| 24 | 8.01 to 8.03- CYCLOPHOSPHAMIDE POWDER (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 25 | CYCLOPHOSPHAMIDE POWDER |
| 26 | CYCLOPHOSPHAMIDE POWDER |
| 27 | CYCLOPHOSPHAMIDE POWDER |
| 28 | 9.01 to 9.03- CYCLOPHOSPHAMIDE RTD (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 29 | CYCLOPHOSPHAMIDE RTD |
| 30 | CYCLOPHOSPHAMIDE RTD |
| 31 | CYCLOPHOSPHAMIDE RTD |
| 32 | 10.1 to 10.3- DACARBAZINE (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 33 | DACARBAZINE |
| 34 | DACARBAZINE |
| 35 | DACARBAZINE |
| 36 | 11.01 to 11.02- DACOMITINIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 37 | DACOMITINIB |
| 38 | DACOMITINIB |
| 39 | 12.01 to 12.06- DARBEPOETIN (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 40 | DARBEPOETIN |
| 41 | DARBEPOETIN |
| 42 | DARBEPOETIN |
| 43 | DARBEPOETIN |
| 44 | DARBEPOETIN |
| 45 | DARBEPOETIN |
| 46 | 13.01 to 13.02- DECITABINE (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 47 | DECITABINE |
| 48 | DECITABINE |
| 49 | 14.01 to 14.02- DURVALUMAB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 50 | DURVALUMAB |
| 51 | DURVALUMAB |
| 52 | 15.01 to 15.04- EVEROLIMUS (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 53 | EVEROLIMUS |
| 54 | EVEROLIMUS |
| 55 | EVEROLIMUS |
| 56 | EVEROLIMUS |
| 57 | 16.01 to 16.02- EVEROLIMUS (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 58 | EVEROLIMUS |
| 59 | EVEROLIMUS |
| 60 | 17.01 to 17.02- L-ASPARAGINASE (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 61 | L-ASPARAGINASE |
| 62 | L-ASPARAGINASE |
| 63 | 18.01 to 18.02- LORLATINIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 64 | LORLATINIB |
| 65 | LORLATINIB |
| 66 | 19.01 to 19.02 -LUSPATERCEPT (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 67 | LUSPATERCEPT |
| 68 | LUSPATERCEPT |
| 69 | 20.01 to 20.02 -MEGESTROL (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 70 | MEGESTROL |
| 71 | MEGESTROL |
| 72 | 21.01 to 21.03 - MITOMYCIN-C (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 73 | MITOMYCIN-C |
| 74 | MITOMYCIN-C |
| 75 | MITOMYCIN-C |
| 76 | 22.01 to 22.02- NANOSOMAL PACLITAXEL LIPID SUSPENSION (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 77 | NANOSOMAL PACLITAXEL LIPID SUSPENSION(NPLS) FOR INJ |
| 78 | NANOSOMAL PACLITAXEL LIPID SUSPENSION(NPLS) FOR INJ |
| 79 | 23.01 to 23.02 - NILOTINIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 80 | NILOTINIB |
| 81 | NILOTINIB |
| 82 | 24.01 to 24.02 -NINTEDANIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 83 | NINTEDANIB |
| 84 | NINTEDANIB |
| 85 | 25.01 to 25.02- OCTREOTIDE (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 86 | OCTREOTIDE |
| 87 | OCTREOTIDE |
| 88 | 26.01 to 26.03- OCTREOTIDE LAR (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 89 | OCTREOTIDE LAR |
| 90 | OCTREOTIDE LAR |
| 91 | OCTREOTIDE LAR |
| 92 | 27.01 to 27.02 -OLAPARIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 93 | OLAPARIB |
| 94 | OLAPARIB |
| 95 | 28.01 to 28.02- OSIMERTINIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 96 | OSIMERTINIB |
| 97 | OSIMERTINIB |
| 98 | 29.01 to 29.03- PEGYLATED INTERFERON ALFA 2B (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 99 | PEGYLATED INTERFERON ALFA 2B |
| 100 | PEGYLATED INTERFERON ALFA 2B |
| 101 | PEGYLATED INTERFERON ALFA 2B |
| 102 | 30.01 to 30.02- PERTUZUMAB+TRASTUZUMAB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 103 | PERTUZUMAB+TRASTUZUMAB |
| 104 | PERTUZUMAB+TRASTUZUMAB |
| 105 | 31.01 to 31.02- POLATUZUMAB VEDOTIN (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 106 | POLATUZUMAB VEDOTIN |
| 107 | POLATUZUMAB VEDOTIN |
| 108 | 32.01 to 32.03 - POMALIDOMIDE (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 109 | POMALIDOMIDE |
| 110 | POMALIDOMIDE |
| 111 | POMALIDOMIDE |
| 112 | 33.01 to 33.02 - RAMUCIRUMAB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 113 | RAMUCIRUMAB |
| 114 | RAMUCIRUMAB |
| 115 | 34.01 to 34.02- RECOMBINANT HUMAN INTERFERON ALFA 2B(QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 116 | RECOMBINANT HUMAN INTERFERON ALFA 2B |
| 117 | RECOMBINANT HUMAN INTERFERON ALFA 2B |
| 118 | 35.01 to 35.02- RUCAPARIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 119 | RUCAPARIB |
| 120 | RUCAPARIB |
| 121 | 36.01 to 36.03- RUXOLITINIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 122 | RUXOLITINIB |
| 123 | RUXOLITINIB |
| 124 | RUXOLITINIB |
| 125 | 37.01 to 37.02 -TECLISTAMAB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 126 | TECLISTAMAB |
| 127 | TECLISTAMAB |
| 128 | 38.01 to 38.02 -S1 THERAPY TEGFUR+GIMERACIL+OTERACIL (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 129 | S1 THERAPY TEGFUR+GIMERACIL+OTERACIL |
| 130 | S1 THERAPY TEGFUR+GIMERACIL+OTERACIL |
| 131 | 39.01 to 39.02- THALIDOMIDE (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 132 | THALIDOMIDE |
| 133 | THALIDOMIDE |
| 134 | 40.01 to 40.03- TOCILIZUMAB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 135 | TOCILIZUMAB |
| 136 | TOCILIZUMAB |
| 137 | TOCILIZUMAB |
| 138 | 41.01 to 41.03- VENETOCLAX (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 139 | VENETOCLAX |
| 140 | VENETOCLAX |
| 141 | VENETOCLAX |
| 142 | 42.01 to 42.02- VINORELBINE (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) |
| 143 | VINORELBINE |
| 144 | VINORELBINE |
| 145 | Name of the Items |
| 146 | ACALABRUTINIB |
| 147 | ALECTINIB |
| 148 | ALL TRANS RETINOIC ACID(TRETINOIN) |
| 149 | ALPELISIB |
| 150 | ALPELISIB |
| 151 | ALTEPLASE |
| 152 | AMIVANTAMAB |
| 153 | AMPHOTERICIN B LIPOSOMAL IN NS |
| 154 | ANASTROZOLE |
| 155 | APALUTAMIDE |
| 156 | ARSENIC TRIOXIDE |
| 157 | ASCIMINIB |
| 158 | ATEZOLIZUMAB |
| 159 | AVELUMAB |
| 160 | BICALUTAMIDE |
| 161 | BLEOMYCIN |
| 162 | BORTEZOMIB |
| 163 | BRENTUXIMAB VEDOTIN |
| 164 | BUSULPHAN |
| 165 | BUSULPHAN |
| 166 | CABAZITAXEL |
| 167 | CAPECITABINE+CYCLOPHOSPHAMIDE |
| 168 | CAPECITABINE+CYCLOPHOSPHAMIDE |
| 169 | CAPMATINIB |
| 170 | CARMUSTINE |
| 171 | CERITINIB |
| 172 | CETUXIMAB |
| 173 | CLADRIBINE |
| 174 | CLOFARABINE |
| 175 | CYCLOPHOSPHAMIDE |
| 176 | DABRAFENIB |
| 177 | DABRAFENIB |
| 178 | DACTINOMYCIN |
| 179 | DARATUMUMAB+HYALURONIDASE FIHJ SUBCUTANEOUS |
| 180 | DAROLUTAMIDE |
| 181 | DAUNORUBICIN |
| 182 | DOCETAXEL NANOSOMAL(LIPID SUSPENSION) |
| 183 | DOCETAXEL NANOSOMAL(LIPID SUSPENSION) |
| 184 | DOCETAXEL NANOSOMAL(LIPID SUSPENSION) |
| 185 | ENTRECTINIB |
| 186 | ENTRECTINIB |
| 187 | ENFORTUMAB VEDOTIN |
| 188 | ENFORTUMAB VEDOTIN |
| 189 | ENZALUTAMIDE SYRUP 150 ML |
| 190 | ERIBULIN |
| 191 | ERYTHROPOIETIN |
| 192 | ERYTHROPOIETIN |
| 193 | ERYTHROPOIETIN |
| 194 | ERYTHROPOIETIN |
| 195 | ERYTHROPOIETIN |
| 196 | ERYTHROPOIETIN |
| 197 | ERYTHROPOIETIN |
| 198 | ERYTHROPOIETIN |
| 199 | ESTRAMUSTINE |
| 200 | ETOPOSIDE |
| 201 | FACTOR VII EPTACOG ALFA(HUMAN RECOMBINANT COAGULATION FACTOR VII ACTIVATED r-DNA ORIGIN) |
| 202 | FACTOR VII EPTACOG ALFA(HUMAN RECOMBINANT COAGULATION FACTOR VII ACTIVATED r-DNA ORIGIN) |
| 203 | FLUDARABINE |
| 204 | FLUDARABINE |
| 205 | FLUNARIZINE |
| 206 | FLUTAMIDE |
| 207 | FOSAPREPITANT DIMEGLUMINE |
| 208 | FOSFESTROL |
| 209 | FOSNETUPITANT+PALONOSETRON |
| 210 | GLITERITINIB |
| 211 | GRANISETRON |
| 212 | GRANISETRON |
| 213 | GRANISETRON MD |
| 214 | GOSERELIN |
| 215 | GOSERELIN |
| 216 | HYDROXYUREA |
| 217 | HYDROXYUREA |
| 218 | IBANDRONIC ACID |
| 219 | IBANDRONIC ACID |
| 220 | IBANDRONIC ACID |
| 221 | IBRUTINIB |
| 222 | IDARUBICIN |
| 223 | INFLEXIMAB |
| 224 | INOTUZUMAB OZOGAMICIN |
| 225 | INTERFERON ALPHA 2B |
| 226 | IPILIMUMAB |
| 227 | IRINOTECAN LIPOSOMAL |
| 228 | ISAVUCONAZOLE |
| 229 | ISAVUCONAZOLE |
| 230 | LEUCOVORIN CALCIUM |
| 231 | LEUCOVORIN CALCIUM |
| 232 | LEUCOVORIN CALCIUM |
| 233 | LEUPROLIDE ACETATE |
| 234 | LOMUSTINE |
| 235 | MELPHALAN |
| 236 | MELPHALAN |
| 237 | MELPHALAN |
| 238 | MERCAPTOPURINE |
| 239 | MERCAPTOPURINE 100 ML |
| 240 | MESNA (3*2 ML PACK) INJ |
| 241 | MESNA 1*2 ML INJ |
| 242 | MESNA RESPIRATORY SOLUTION |
| 243 | METHOTREXATE |
| 244 | METHOTREXATE |
| 245 | METHOTREXATE |
| 246 | METHOTREXATE |
| 247 | METHOTREXATE |
| 248 | METHOTREXATE |
| 249 | MIDOSTAURIN |
| 250 | MITOXANTRONE |
| 251 | MYCOBACTERIUM W.(HEAT KILLED) IMMUNOMODULATOR INJ |
| 252 | NELARABINE |
| 253 | NIMOTUZUMAB |
| 254 | OBINUTUZUMAB |
| 255 | ONDANSETRON |
| 256 | ONDANSETRON |
| 257 | ONDANSETRON |
| 258 | ONDANSETRON |
| 259 | ONDANSETRON 30 ML SYRUP |
| 260 | ONDANSETRON MD |
| 261 | ONDANSETRON MD |
| 262 | ONDANSETRON ODS |
| 263 | ONDANSETRON ODS |
| 264 | PACLITAXEL ALBUMIN BOUND NANO PARTICLE |
| 265 | PALANOSETRON |
| 266 | PALANOSETRON |
| 267 | PALANOSETRON |
| 268 | PALANOSETRON+NETUPITANT |
| 269 | PALANOSETRON+NETUPITANT |
| 270 | PANITUMUMAB |
| 271 | PEGASPARGASE |
| 272 | PEMBROLIZUMAB |
| 273 | PERTUZUMAB |
| 274 | PLERIXAFOR |
| 275 | PROCARBAZINE |
| 276 | RASBURICASE |
| 277 | REGORAFENIB |
| 278 | RELUGOLIX |
| 279 | RIBOCICLIB |
| 280 | ROMIPLOSTIM |
| 281 | SARGRAMOSTIM |
| 282 | SIROLIMUS |
| 283 | SORAFENIB |
| 284 | TAMOXIFEN |
| 285 | TAMOXIFEN |
| 286 | TEGFUR+URACIL |
| 287 | TEPOTINIB |
| 288 | THIOGUANINE |
| 289 | THIOTEPA |
| 290 | THIOTEPA |
| 291 | THYROTROPIN ALFA |
| 292 | TOPOTECAN |
| 293 | TORIPALIMAB |
| 294 | TRABECTEDIN |
| 295 | TRAMETINIB |
| 296 | TRASTUZUMAB DERUXTECAN |
| 297 | TRIFLURIDINE+TIPIRACIL |
| 298 | TRIFLURIDINE+TIPIRACIL |
| 299 | TRIPTORELIN |
| 300 | TRIPTORELIN |
| 301 | TRIPTORELIN PAMOATE |
| 302 | TREMELIMUMAB |
| 303 | TUCATINIB |
| 304 | TUCATINIB |
| 305 | VALGANCICLOVIR |
| 306 | VINBLASTIN |
| 307 | VINCRISTINE |
| 308 | VINCRISTINE |
| 309 | VORICONAZOLE |
| 310 | ZOLEDRONIC ACID |
| 311 | ZOLEDRONIC ACID |
